Triple low-dose antihypertensive pill reduced recurrent stroke after intracerebral hemorrhage

1. In clinically stable patients with prior intracerebral hemorrhage, a fixed-dose combination pill containing three low-dose antihypertensive agents reduced recurrent stroke compared with placebo when added to standard care.

2. The triple pill also improved blood-pressure control and reduced major cardiovascular events, though treatment discontinuation due to adverse events was more common.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Blood-pressure reduction is the only proven strategy to reduce recurrence after spontaneous intracerebral hemorrhage, but long-term control is often inadequate because of poor adherence, insufficient treatment intensification, and uncertainty regarding the best treatment approach. Fixed-dose combination therapy may simplify treatment and improve blood-pressure control while limiting side effects. This multinational randomized controlled trial investigated whether a single pill containing low-dose telmisartan, amlodipine, and indapamide could reduce recurrent stroke in patients with prior intracerebral hemorrhage. Overall, it was found that the triple pill significantly lowered the incidence of recurrent stroke compared with placebo. It was also associated with improved blood-pressure control and reduced major cardiovascular events. Serious adverse events were similar between groups, although discontinuation due to adverse events was more common with the triple pill, largely because of protocol-mandated discontinuation after increases in serum creatinine. The generalizability of these findings was limited by the active run-in phase, which excluded patients unable to tolerate or adhere to treatment, and by the fact that most participants were enrolled in a single country. Nonetheless, this study suggests that a fixed-dose low-dose combination pill may be an effective strategy for secondary prevention after intracerebral hemorrhage.

Click to read the study in NEJM

Relevant Reading: Association Between Blood Pressure Control and Risk of Recurrent Intracerebral Hemorrhage

In-Depth [randomized controlled trial]: This multinational, double-blind, placebo-controlled trial enrolled adults with spontaneous intracerebral hemorrhage who were clinically stable and had a systolic blood pressure of 130 to 160 mm Hg. After a 2-week active run-in phase, patients who tolerated therapy were randomly assigned to continue a once-daily triple pill containing telmisartan, amlodipine, and indapamide or to receive matching placebo in addition to standard antihypertensive care. A total of 1670 patients underwent randomization, with 833 assigned to the triple-pill group and 837 assigned to placebo. Baseline characteristics were balanced between groups. At a median follow-up of 2.5 years, recurrent stroke occurred in 4.6% of patients in the triple-pill group and 7.4% of those in the placebo group (hazard ratio, 0.61; 95% confidence interval [CI], 0.41 to 0.92). Blood-pressure control at 6 months, defined as systolic blood pressure less than 130 mm Hg, was achieved in 49.9% and 26.4% of patients, respectively. Major cardiovascular events occurred in 6.6% of patients receiving the triple pill and 9.8% receiving placebo (p=0.04). The reduction in recurrent stroke appeared to be driven primarily by fewer recurrent intracerebral hemorrhages, which occurred in 1.8% and 4.4% of patients, respectively. Serious adverse events occurred in 23.2% of patients in the triple-pill group and 26.0% in the placebo group. Early discontinuation due to adverse events was more common with the triple pill (13.6% vs. 6.0%), most often due to a protocol-mandated discontinuation after a rise in serum creatinine (7.1% vs. 2.5%). In summary, a fixed-dose triple antihypertensive pill improved blood-pressure control and reduced recurrent stroke after intracerebral hemorrhage.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.